-
FDA Approves Innovative Combination Therapy to Eradicate Helicobacter Pylori Infection
Recently, Phathom Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved Voquezna Triple Pak
2022-05-05 15:18 -
AstraZeneca's Ultomiris Third Indication Approved by US FDA!
Recently, AstraZeneca announced that the new indication of Ultomiris (ravulizumab) has been approved by the US Food and Drug Administration (FDA) for ...
2022-05-05 09:38 -
Pfizer Q1: Paxlovid Revenue of $1.47 Billion Comirnaty Revenue of $13.23 Billion
Pfizer's estimated sales of Paxlovid in 2022 are $22 billion, and Q1 revenue in 2022 is $1.47 billion, which is lower than expected.
2022-05-05 09:19 -
Four Times The Premium to Acquire Checkmate, A Leading Pharmaceutical Company, Regeneron's Advanced ...
REGENERON and Checkmate today jointly announced that the two companies have signed a definitive agreement whereby Regeneron will acquire Checkmate com...
2022-04-29 17:54 -
First Generic Drug! Qilu Pharmaceuticals’ 'Dolutegravir' Submission Approved
On April 24, the CDE official website showed that Qilu Pharmaceutical's "dotegravir sodium tablet" application for listing was accepted. Dolutegravir ...
2022-04-29 16:39 -
Sanofi's 2022Q1 Performance: China Increased by 13.4%! Dupixent Up 45.7%
On April 28, Sanofi announced its 2022Q1 results, achieving revenue of 9.674 billion euros, a year-on-year increase of 8.6%.
2022-04-29 12:00 -
Improved Activity and Durability New Generation of Ready-to-Use CAR-T Therapy Receives FDA Orphan Dr...
Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic chimeric antigen receptor T-cell (AlloCAR T) products targeting ...
2022-04-29 11:16 -
FDA Approves New Drug for BMS Cardiomyopathy
On April 29, Bristol-Myers Squibb's (BMS) mavacamten was approved by the FDA for the treatment of adult patients with obstructive hypertrophic cardiom...
2022-04-29 10:43 -
FDA Approves Pfizer’s Phase 3 Clinical Trial of DMD Gene Therapy
Today, Pfizer announced that the U.S. Food and Drug Administration (FDA) has notified the company that the Phase 3 clinical trial of its gene therapy ...
2022-04-29 09:15 -
Dyne Marine Bio Submits A Marketing Application for Atomoxetine Hydrochloride Capsules
On April 26, Shandong Dayin Marine Biopharmaceutical submitted a 4-type generic listing application for atomoxetine hydrochloride capsules.
2022-04-28 17:27
Hot News
- ExxonMobil Launches $10 Billio... Jul 17, 2025
- Global MDI/TDI Plants Enter Pe... Jul 23, 2025
- Europe Faces Unprecedented Pet... Jul 23, 2025
- Guangdong Jieyang Puts into Op... Jul 16, 2025
- BASF Launches Second Round of ... Jul 24, 2025
Related Products
Related Producers
